Dec 31, 2023

Ekso Bionics Q4 2023 Earnings Report

Ekso Bionics reported a 36% increase in revenue, reaching $4.8 million, and a gross profit of $2.4 million with a 49% gross margin for the quarter ended December 31, 2023.

Key Takeaways

Ekso Bionics reported record annual revenue of $18.3 million in 2023, driven by strong demand for EksoHealth devices. Fourth-quarter revenue increased by 36% to $4.8 million, with a gross profit of $2.4 million and a 49% gross margin. The company sold 38 EksoHealth units in Q4 2023.

Achieved record revenue of $18.3 million for the full year 2023, a 42% increase year-over-year.

Revenue for the quarter ended December 31, 2023, was $4.8 million, a 36% increase compared to the same period in 2022.

Gross profit for the quarter ended December 31, 2023, was $2.4 million, a 41% increase from the same period in 2022.

Net loss applicable to common stockholders for the quarter ended December 31, 2023, was $3.2 million, or $0.22 per basic and diluted share.

Total Revenue
$4.85M
Previous year: $3.55M
+36.5%
EPS
-$0.22
Previous year: -$0.24
-8.3%
Gross Profit
$2.4M
Previous year: $1.68M
+43.0%
Cash and Equivalents
$8.6M
Previous year: $20.5M
-58.1%
Free Cash Flow
-$1.63M
Previous year: -$3.7M
-56.0%
Total Assets
$28.9M
Previous year: $40.9M
-29.3%

Ekso Bionics

Ekso Bionics

Forward Guidance

The company remains focused on expanding the reach of its exoskeleton devices and believes its robust portfolio and scalable commercial strategy position it well for long-term growth.